source
- Rezera delays $200M IPO amid weak market conditionsRezera, a biotech developing drugs for cardiovascular and inflammatory diseases, announced that it will not proceed with its planned initial public offering that had been scheduled for Friday. The…
- Bristol Myers shifts R&D leadership to chief medical officer Cristian Massacesi as research head Robert Plenge departsBristol Myers Squibb announced a reorganization of its research and development structure. The company said chief medical officer and head of development Cristian Massacesi will assume the duties…